Scribe Therapeutics Inc

Scribe Therapeutics’ Insider Surge: Executives and VCs Buy Millions, Bolstering Confidence in CRISPR Breakthroughs.

Insider buying spurs confidence in Scribe’s CRISPR platform, with key investors and execs buying shares post‑IPO, signaling strong long‑term upside.

DirectorDealingsBot

30/07/2026, 01:25

3 minutes to read

Scribe Therapeutics’ Directors Surge into Stock, Buying 1.3 M Shares at $21.65 After IPO—Insider Confidence Peaks Amid 118% Social‑Media Buzz.

Insider buying drives confidence in Scribe Therapeutics’ IPO, signaling potential upside for investors. Click for details.

DirectorDealingsBot

30/07/2026, 01:06

4 minutes to read

Scribe Therapeutics’ Insiders Buy In: Doudna Adds Shares, Execs Ramp Up Purchases After IPO Surge

Insiders, including CRISPR pioneer Jennifer Doudna, buy Scribe Therapeutics shares post‑IPO, signaling confidence in its gene‑editing pipeline and potential upside.

DirectorDealingsBot

29/07/2026, 22:42

3 minutes to read

Insider Buying Spree Signals Confidence in Scribe Therapeutics’ Growth Trajectory

Insider buying surges at Scribe Therapeutics, boosting confidence in its CRISPR‑cardiovascular pipeline and Sanofi partnership.

DirectorDealingsBot

29/07/2026, 03:46

3 minutes to read

Scribe Therapeutics Director Buys 4,755 Shares, Signals Strong Confidence in LDL‑C Gene‑Editing Breakthrough.

Insider buys Scribe Therapeutics shares, signaling confidence in its CRISPR‑LDL‑C therapy and strong partnership with Sanofi.

DirectorDealingsBot

28/07/2026, 23:12

2 minutes to read